StockGuide AI
Track Stocks
EN RU ES
Stryker

Stryker

Price: 308.84

Company and Business Model

Stryker Corporation is a leading medical technology company that develops and manufactures a range of products in the healthcare sector. Its core offerings include surgical equipment, orthopedic implants, neurotechnology, and spine products. Major business segments consist of Orthopedics, MedSurg, and Neurotechnology & Spine. The primary revenue sources are derived from sales of surgical instruments, implants, and related services.

Investment Profile

The investment profile of Stryker is more aligned with value investors, given its current dividend yield and established market presence. However, recent revenue declines and earnings surprises may indicate challenges in growth potential. The stock may appeal to those seeking stability rather than aggressive growth.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
8.73 OK
Revenue QoQ — quarter-over-quarter revenue growth
-16.1% ↓
EPS surprise
-12.8% worse than expected
20d volatility
1.8% stable
Dividend yield
1.4% moderate last ex-date: 2026-06-30
FMP / FinFeed data updated: 2026-06-11

Forecast impact

negative
Target Lowered · Leerink Partners · valid until 2026-07-05 · updated 2026-06-11
Target +31.8% target fill 75.9%
Reaction D5 -4.18% · D10 pending market trust
Impact Potential -4 · Risk +3 up to 30 days or until target is reached
Reco: Sell Potential: 33 Risk: 75 Updated: 2026-06-11 05:26
How recommendation works
Why AI thinks so:
Weak fundamentals and negative momentum raise concerns.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-05-10 02:45 Hold Sell scenario_deterioration
2026-05-08 15:19 — Hold Weak fundamentals and negative momentum indicate high risk.
2026-05-08 06:38 Hold Hold Компания Stryker демонстрирует значительное снижение выручки и негативные тренды на фондовом рынке, что указывает на высокие риски для инвесторов. Учитывая текущие показатели и негативные прогнозы, рекомендуется рассмотр
Analyst forecasts
Date Analyst Action Target Price Then
2026-06-05 09:16 Leerink Partners Target Lowered — → 407 301.21
2026-05-04 13:39 Truist Financial Target Lowered 380 → 330 293.44
2026-05-04 09:27 Barclays Target Lowered 469 → 394 294.73